{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062039","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.256094+00:00","generated_at":"2026-06-08T06:04:48.450321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight Q3 revenue up 76% to $22.2M; raises FY2023 guidance","bullets":["Q3 revenue $22.2M (+76% YoY); net loss $(12.4)M, EPS $(0.35); adjusted net loss $(6.9)M, adj. EPS $(0.19)","Sold 66 LDDs (installed base 589, +72% YoY); LAL procedure volumes 13,657 (+107% YoY)","Raised FY2023 revenue guidance to $85-87M (prior $81-86M); gross margin guidance 60-61% (prior 58-60%)","Eliminated remaining $20M term loan; expects to reduce annualized interest expense by ~$5.6M","Raised $11.7M net via ATM facility; cash/short-term investments $131.9M at quarter end"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062039","json":"https://secwatch.observer/filing/0000950170-23-062039.json","markdown":"https://secwatch.observer/filing/0000950170-23-062039.md","text":"https://secwatch.observer/filing/0000950170-23-062039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/0000950170-23-062039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/rxst-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:04:48.450321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9dcd3e990b5388f9d4afc8db9da72f64bfa6771","claim":"RxSight, Inc. reported three and nine months ended September 30, 2023 results: revenue $22.2 million, net income $(12.4) million, EPS $(0.35) per basic and diluted share. Guidance raised.","evidence_excerpt":"cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights • Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: • The sale of 66 Light Delivery Devices (LDDTMs), representing a 35% increase in unit sales compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/0000950170-23-062039-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$22.2 million"},{"label":"Net income","value":"$(12.4) million"},{"label":"EPS","value":"$(0.35) per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}